Therapeutic targets of fibrosis: Translational advances and current challenges
Open Access
- 17 October 2023
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 180 (22) , 2839-2845
Abstract
In a physiological context, the extracellular matrix (ECM) provides an important scaffold for organs. Dysregulation of ECM in disease conditions, characterised by excess deposition of connective tissue and extracellular matrix in response to a pathological insult, is a key driver of disease progression in multiple organs. The resultant fibrosis is predominantly an irreversible process and directly contributes to, and exacerbates, dysfunction of an affected organ. This is particularly paramount in the kidney, liver, heart and lung. A hybrid Joint Meeting of NC‐IUPHAR and British Pharmacological Society was held in Paris and via a webinar in November 2020, when two successive sessions were devoted to translational advances in fibrosis as a therapeutic target. On the upsurge of response to these sessions, the concept of a special themed issue on this topic emerged, and is entitled Translational Advances in Fibrosis as a Therapeutic Target. In this special issue, we seek to provide an up‐to‐date account of the diverse molecular mechanisms and causal role that fibrosis plays in disease progression (contributing to, and exacerbating, dysfunction of affected organs). Recent developments in the understanding of molecular targets involved in fibrosis, and how their actions can be manipulated therapeutically, are included.LINKED ARTICLES: This article is part of a themed issue on Translational Advances in Fibrosis as a Therapeutic Target. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v180.22/issuetocKeywords
This publication has 20 references indexed in Scilit:
- Basic Mechanisms of Diabetic Heart DiseaseCirculation Research, 2020
- Epidemiology of Non-alcoholic Fatty Liver Disease in North AmericaCurrent Pharmaceutical Design, 2020
- European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart FailureEuropean Journal of Heart Failure, 2019
- Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection FractionJournal of the American Heart Association, 2019
- Sex differences in the response to angiotensin II receptor blockade in a rat model of eccentric cardiac hypertrophyPeerJ, 2019
- Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular diseaseBiology of Sex Differences, 2019
- Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection FractionJACC: Heart Failure, 2018
- Necroptosis: Mechanisms and Relevance to DiseaseAnnual Review of Pathology: Mechanisms of Disease, 2017
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Sex‐Specific Impact of Aldosterone Receptor Antagonism on Ventricular Remodeling and Gene Expression after Myocardial InfarctionClinical and Translational Science, 2009